[1] |
田艳娟. 利格列汀联合格列美脲对肥胖2型糖尿病患者血糖控制及体质量指数的影响[J]. 北方药学, 2019, 16(3): 68-69.
|
[2] |
袁明霞,袁申元,傅汉等. 北京社区2型糖尿病患者颈围与中心性肥胖及代谢综合征的相关性[J]. 2010, 12(12): 1059-1061.
|
[3] |
中华医学会内分泌学分会. 中国2型糖尿病合并肥胖综合管理专家共识[J]. 药品评价, 2016, 13(17): 5-12.
|
[4] |
宋天阔,黄苛伊,王殿刚等. 肥胖与2型糖尿病常见因素的研究[J]. 饮食保健, 2019, 6(5): 286-287.
|
[5] |
李月红,汪辉. 人体测量指标作为中国城市人群心血管危险因素的预测因素[J]. 德州学院学报, 2018, 34(4): 89-96.
|
[6] |
刘淑霞,王小红,朱春. 腹部脂肪面积定量CT测定及其与肥胖并发症关系的临床研究[J].影像研究与医学应用, 2018, 2(1): 176-177.
|
[7] |
中华医学会糖尿病学分会,中国2型糖尿病防治指南(2017年版)[J],中华糖尿病杂志, 2018, 10(1): 4-7.
|
[8] |
郝春满,李振水,许英霞等. 2型糖尿病内脏脂肪面积与肾小球滤过率相关分析[J]. 医学研究杂志, 2018, 47(1): 32-34.
|
[9] |
Kuwahara K, Honda T, Nakagawa T, et al. Body mass index trajectory patterns and changes in visceral fat and glucose metabolism before the onset of type 2 diabetes[J]. Sci Rep, 2017, 7(7): 43521.
|
[10] |
Maksymets T, Sorochka M, Bondarenko O,et al. Comparison of metabolic profile of obese non-diabetic patients with coronary artery disease depending on atorvastatin dose[J]. Wiad Lek, 2019, 72(5 cz 1): 846-850
|
[11] |
Haberka M, Stolarz-Skrzypek K, Biedroń M,et al. Obesity, Visceral Fat, and Hypertension-Related Complications[J]. Metab Syndr Relat Disord, 2018, 5.
|
[12] |
Matsha TE, Ismail S, Speelman A, et al. Visceral and subcutaneous adipose tissue association with metabolic syndrome and its components in a South African population[J]. Clin Nutr ESPEN, 2019, 32: 76-81.
|
[13] |
Zhang X, Zhu C, Gao J, et al. Gender difference in the relationship between serum uric acid reduction and improvement in body fat distribution after laparoscopic sleeve gastrectomy in Chinese obese patients: a 6-month follow-up[J]. Lipids Health Dis, 2018, 17(1): 288.
|
[14] |
Albracht-Schulte K, Rosairo S, Ramalingam L, et al. Obesity, adipocyte hypertrophy, fasting glucose, and resistin are potential contributors to nonalcoholic fatty liver disease in South Asian women[J]. Diabetes Metab Syndr Obes, 2019, 10(12): 863-872.
|
[15] |
葛均波, 徐永健等. 肥胖症[M],内科学.8版.北京:人民卫生出版社, 2013. 771.
|
[16] |
杨光燃,袁申元,傅汉菁, 等. 颈围、腰围、腰臀比对2型糖尿病患者超重、肥胖及代谢综合征评价作用的比较研究[J]. 中国全科医学, 2016, 19(7): 781-785.
|
[17] |
刘惠双. 腹腔内脏脂肪面积与慢性疾病相关性研究[J].中国现代药物应用, 2016, 10(2): 88-89.
|
[18] |
林毅辉,雷闽湘,蒋建家, 等. 肥胖2型糖尿病患者腹腔内脂肪面积与胰岛素抵抗的相关性[J].山西医科大学学报, 2016, 47(10): 922-925.
|
[19] |
徐艺文,朱惠娟. 内脏脂肪的测定及临床应用进展[J].医学综述, 2016, 22(13): 2575-2578.
|
[20] |
张悦,王迪,曹宏伟, 等. 男性2型糖尿病高三酰甘油-腰围表型与内脏脂肪面积相关性研究[J].河北医药, 2017, 39(10): 1524-1526.
|
[21] |
谭擎缨,姚佳琦,王秀景等. 腹腔内脏脂肪面积与2型糖尿病及血清胰岛素的相关研究[J]. 东南国防医药, 2015, 17(1): 12-15.
|
[22] |
卢姗,李群,曾珊. MNT减少2型糖尿病内脏脂肪的研究[J].南京医科大学学报, 2014, 34(11): 1542-1544,1549.
|
[23] |
蒋建家,孙炳庆,庄玉君, 等. 内脏脂肪蓄积与血尿酸和代谢综合征的关系[J].福建医科大学学报, 2009, 43(4): 327-330.
|
[24] |
Alba DL, Farooq JA, Lin MYC,et al. Subcutaneous Fat Fibrosis Links Obesity to Insulin Resistance in Chinese Americans[J]. J Clin Endocrinol Metab, 2018, 103(9): 3194-3204.
|
[25] |
孙博喻,张冰,林志健, 等. 腹型肥胖的研究进展[J].中华中医药学刊, 2015, 33(1): 80-83.
|
[26] |
刘彬彬,蒋韬,李炎, 等. 男性血尿酸与腹型肥胖的相关性研究[J].河北医药, 2015, 37(17): 2675-2677.
|
[27] |
Rodríguez-López CP, González-Torres MC, Cruz-Bautista I, et al. Visceral obesity, skeletal muscle mass and resistin in metabolic syndrome development[J]. Nutr Hosp, 2019, 36(1): 43-50.
|
[28] |
Lee A, Kim YJ, Oh SW, et al. Cut-Off Values for Visceral Fat Area Identifying Korean Adults at Risk for Metabolic Syndrome[J]. Korean J Fam Med, 2018, 39(4): 239-246.
|